Dr. Prashant Bhardwaj, Ph.D.’s Post

The rise of affordable biologics in the biopharmaceutical industry is a diverse and interconnected innovation system that is supported by long-term funding for basic research at universities and national laboratories, as well as partnerships between innovative startups and large pharmaceutical companies. The system also includes public and private research centers, philanthropic foundations, a diverse range of small and medium-sized businesses, contract research organizations, contract manufacturing organizations, and pharmacies. This distributed and interconnected structure—a defining feature of biopharmaceutical innovation system is unparalleled in its ability to bring lifesaving and health-enhancing drugs and medical devices to market. This distributed and interconnected structure of the biopharmaceutical innovation —has an unprecedented ability to bring QoL and health-enhancing drugs and medical devices to market. While exact estimates are difficult to find, the Association of University Technology Managers reports that, from 1996 until pre-pandemic era, over 200 new drugs and vaccines were developed through university-industry partnerships made possible by the Bayh-Dole Act. The Bayh-Dole Act incentivized universities and professors to move innovation to the marketplace, providing a pathway for biomedical research to be translated into new therapies.

The increasing confluence of biologics, biosimilars, vaccines, and emerging technologies like cell and gene therapy, the Indian biopharma industry is poised for a leap. The country's strength in science, research, and manufacturing, coupled with the ongoing evolution of advanced technologies, highlights India's potential to emerge as a global biopharma hub. However, integrating strategic policymaking, fostering research and innovation, and fortifying public-private partnerships are crucial to realise this potential completely and sustainably.

To my research club in the UK. BNRC’s first symposium will be 9 a.m.-4 p.m., Sept. 26, in the E.S. Good Barn’s Gorham Hall. This Bioelectronics and Nanomedicine Research Center combines some of the UK’s key strengths: materials science, engineering and biomedical research to bring innovative researchers in these critical fields to our campus to showcase cutting-edge research that can be leveraged to advance the health.

These Global Biopharmaceutical Diplomacies strengthen "Global Health Security, Global Public Health, and International Relations" and address supply shortages. This alliance was inaugurated in San Diego during the Bio International Convention 2024. It is an alliance of India, South Korea, Japan, the US, and the European Union to put joint efforts into building a resilient supply chain in the biopharmaceutical sector. They acknowledged that the production of essential raw materials and ingredients is concentrated in a few countries and agreed to work together to build a detailed pharmaceutical supply chain map. The alliance was launched in response to the drug supply shortages experienced during the Covid-19 pandemic. The Bio International Convention is the premier event for the biotechnology industry, bringing together over 20,000 leaders from around the world. It represents the entire biotech ecosystem, from public pharmaceutical companies and biotech startups to academia, non-profits, and government agencies. The participants emphasized the importance of a reliable and sustainable supply chain and agreed to coordinate the respective countries' bio policies, regulations, and research and development support measures.

Nanotechnology= NanoEra Nanotechnology involves the use of nanoscale materials and devices to improve diagnostics, therapeutics, and drug delivery. It enables targeted treatment at the cellular level, thereby minimizing side effects and enhancing the efficacy of therapies. This innovative approach is revolutionizing various medical fields, including oncology, regenerative medicine, and diagnostic imaging. The current outlook for the nanotechnology in the medical market is highly promising, driven by advancements in nanomaterials and increasing investments in research and development.

The rapid pace of progress—including the emergence of pharmacy-benefit biosimilars—reflects the investment in this space and the growth forecasted over the next half-decade, when the market could reach more than $100 billion.

Nanotechnology = NanoEra #Nanomedicine The mRNA technology relies on nanotechnology. mRNA molecules degrade too fast in the body to be effective without encapsulating them in nanoparticles. This process could open up a bright future for nanotechnology in medicine and will hopefully greatly improve health care.

Nanotehnology= NanoEra

Predictive artificial intelligence (AI)/Predictive Medicine is the next big thing in healthcare. The fast-evolving realm of early prediction and treatment of illnesses promises a big shift in the medical universe. Predictive artificial intelligence (AI) in drug development with machine learning to identify patterns in past events and make predictions about future events. AI/ML have big potential for small molecules. As advanced therapeutic drugs for most human proteins, there are no small molecules known to bind them chemically. Another trend has been a growth in the number of products on an accelerated development pathway, typically because of the unmet needs of a particular patient group and analyze a significant amount of data relating to manufacture, stability, solid form landscape, and formulation are required early in the development timeline to support safe and rapid progression.

Bye-bye hurdles to biosimilar access: Removed Switch Studies as Zero Block to Wider Biosimilar Use. As the interchangeability requirements are removed, this could positively impact the adoption of biosimilars and allow for automatic substitutions at the pharmacy level. This change could lead to sustainability in the market, less expensive go to market strategies for manufacturers, and more affordable medications for both the health care system and patients.